Cost-effectiveness estimates reported for tumor necrosis factor blocking agents in rheumatoid arthritis refractory to methotrexate - A brief summary

Journal of Rheumatology

Volumn 32, Issue SUPPL. 72, 2005, Pages 51-53

  Maetzel, Andreas ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Arthritis; Biologic therapy; Cost benefit analysis

Indexed keywords

ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

BIOLOGICAL THERAPY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; HEALTH CARE COST; HUMAN; MEDICAL CARE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUALITY OF LIFE; REFRACTORY PERIOD; RHEUMATOID ARTHRITIS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG ANTAGONISM; ECONOMICS; IMMUNOLOGY; REVIEW; SWEDEN; UNITED KINGDOM; UNITED STATES;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HUMANS; METHOTREXATE; SWEDEN; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 17144420853     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Pausjenssen AM, Detsky AS. Guidelines for measuring the costs and consequences of adopting new pharmaceutical products: are they on track? Med Decis Making 1998;18 Suppl:S19-S22.
2. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme [see comments]. JAMA 2000;283:2116-21.
3. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effective ness in health and medicine. New York, Oxford: Oxford University Press; 1996.
4. Brouwer WB, Koopmanschap MA, Rutten FF. Patient and informal caregiver time in cost-effectiveness analysis. A response to the recommendations of the Washington Panel. Int J Technol Assess Health Care 1998;14:505-13.
5. Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992;34:1005-10.
6. Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum 2002;47:655-61.
7. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
8. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:1637-41.
9. Organisation for Economic Co-operation and Development. Purchasing power parities. Internet. Cited September 5, 2004. Available from: http://www.oecd.org/dataoecd/61/54/18598754.pdf
10. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000;43:2316-27.
11. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
12. Maini RN, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
13. Wolfe F, Michaud K, Pincus T. Do rheumatology cost-effectiveness analyses make sense? Rheumatology Oxford 2004;43:4-6.
14. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
15. Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326-35.
16. Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002;6:1-110.
17. Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK [see comment]. Rheumatology Oxford 2004;43:62-72.